Protease inhibitors as immunomodulatory drugs for HIV infection (Q46312645)

21 December 2017

title

Protease inhibitors as immunomodulatory drugs for HIV infection (English)

1 reference

21 December 2017

author name string

Deeks SG

series ordinal

1

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

21 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

21 December 2017

volume

82

1 reference

21 December 2017

issue

3

1 reference

21 December 2017

page(s)

248-250

1 reference

21 December 2017

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

The dynamics of CD4+ T-cell depletion in HIV disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100205

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100205

1 reference

21 December 2017

PubMed ID

17700590

1 reference

21 December 2017